Monitoring the microcirculation of patients with advanced lungcancer treated with bevacizumab and chemotherapy using optical spectroscopy.

Recruiting

• Conditions: lungcancer; 10038666

• Registration Number: NL-OMON30524
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

· suspected endoscopically visible tumour
· written informed consent
· histologycally or cytologicoly documented inoperable advanged stage IV NSCLC or extensive SCLC
· WHO 1-2
· Life expectancy > 12weeks
· Adequate hemologycal/liver/renal function
· INR< 1,5
· In case of female, not pregnant or breastfeeding

Exclusion Criteria

none

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>oxygen saturation and vesseldiameter in the tumour before and after<br /><br>chemotherapy with or without bevacizumab</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>survival of the patients</p><br>